Agios

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agios and other ETFs, options, and stocks.

About AGIO

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. 

CEO
Brian M. Goff
CEOBrian M. Goff
Employees
540
Employees540
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2007
Founded2007
Employees
540
Employees540

AGIO Key Statistics

Market cap
1.69B
Market cap1.69B
Price-Earnings ratio
-3.92
Price-Earnings ratio-3.92
Dividend yield
Dividend yield
Average volume
1.17M
Average volume1.17M
High today
$28.70
High today$28.70
Low today
$28.08
Low today$28.08
Open price
$28.21
Open price$28.21
Volume
229.33K
Volume229.33K
52 Week high
$46.00
52 Week high$46.00
52 Week low
$22.24
52 Week low$22.24

Stock Snapshot

As of today, Agios(AGIO) shares are valued at $28.49. The company's market cap stands at 1.69B, with a P/E ratio of -3.92.

As of 2026-05-13, Agios(AGIO) stock has fluctuated between $28.08 and $28.70. The current price stands at $28.49, placing the stock +1.5% above today's low and -0.7% off the high.

Agios(AGIO) shares are trading with a volume of 229.33K, against a daily average of 1.17M.

During the past year, Agios(AGIO) stock moved between $22.24 at its lowest and $46.00 at its peak.

During the past year, Agios(AGIO) stock moved between $22.24 at its lowest and $46.00 at its peak.

AGIO News

TipRanks 22h
Agios Pharma submits sNDA to FDA for U.S. accelerated approval of mitapivat

Agios Pharmaceuticals (AGIO) announced the submission of its supplemental New Drug Application to the U.S. FDA for the U.S. accelerated approval of mitapivat, a...

TipRanks 22h
Agios Pharmaceuticals to present mitapivat data at EHA Congress

Agios Pharmaceuticals (AGIO) announced that new data on mitapivat, an oral pyruvate kinase activator, will be featured in oral and poster presentations during t...

Nasdaq 1d
Agios Files FDA Application Seeking Accelerated Approval Of Mitapivat For Sickle Cell Disease

(RTTNews) - Rare disease drugmaker Agios Pharmaceuticals Inc. (AGIO) on Tuesday announced the submission of a supplemental New Drug Application, or sNDA, to the...

Agios Files FDA Application Seeking Accelerated Approval Of Mitapivat For Sickle Cell Disease

Analyst ratings

70%

of 10 ratings
Buy
70%
Hold
30%
Sell
0%

People also own

Based on the portfolios of people who own AGIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.